Introduction – Core User Needs & Industry Context

Pharmaceutical manufacturers require high-purity active pharmaceutical ingredients (APIs) for the production of non-sedating antihistamines used in allergic rhinitis and chronic urticaria. First-generation antihistamines cause drowsiness; second-generation options with improved safety profiles are preferred. Bilastine API — the active substance in bilastine formulations, a selective histamine H1 receptor antagonist with anti-allergic properties — solves these challenges. It is commonly used in tablet and oral solution production, complying with pharmacopeial standards for purity, impurity profile, and physicochemical characteristics. According to the latest industry analysis, the global market for Bilastine API was estimated at US$ 16.20 million in 2025 and is projected to reach US$ 26.35 million by 2032, growing at a CAGR of 7.3% from 2026 to 2032. The global sales volume in 2024 was 31.93 metric tons, with an average price of US$ 476 per kilogram.

Global Leading Market Research Publisher QYResearch announces the release of its latest report "Bilastine API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bilastine API market, including market size, share, demand, industry development status, and forecasts for the next few years.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098787/bilastine-api

1. Core Keyword Integration & Purity Classification

Three key concepts define the bilastine API market: Non-Sedating Antihistamine, H1 Receptor Antagonist, and Allergic Rhinitis Treatment. Based on purity level, bilastine API is classified into two types:

Purity 98%-99%: Standard grade for tablet formulations. Suitable for most commercial products. ~40% market share.

Purity Above 99%: High-purity grade for oral solutions and premium formulations. ~60% share, largest segment.

2. Industry Layering: Tablets vs. Oral Solutions – Divergent Requirements

Aspect Tablets Oral Solutions
Primary patient population Adults, older children Pediatric, elderly, dysphagia
Key requirement Compressibility, stability Solubility, taste masking
Preferred purity 98-99% >99% (higher purity)
Regulatory standard USP, EP USP, EP (stricter for liquids)
Market share (2025) ~80% ~20%
Exclusive observation: The tablets segment dominates (80% share), driven by adult allergic rhinitis and urticaria treatment. The oral solutions segment is fastest-growing (CAGR 8.5%), fueled by pediatric and geriatric patient populations.

3. Bilastine vs. Other Second-Generation Antihistamines

Feature Bilastine Cetirizine Loratadine Fexofenadine Levocetirizine
Generation Second Second Second Second Third
Sedation risk Very low Low Very low Very low Very low
Onset of action 1-2 hours 1 hour 2-3 hours 1-2 hours 1 hour
Duration 24 hours 24 hours 24 hours 24 hours 24 hours
Food effect Reduced absorption No No No No
Cardiac safety No QTc prolongation No No No No
Pediatric approval ≥12 years ≥6 months ≥2 years ≥6 months ≥6 months
4. Recent Data & Technical Developments (Last 6 Months)

Between Q4 2025 and Q1 2026, several advancements have reshaped the bilastine API market:

Orodispersible tablet formulations: New bilastine orally disintegrating tablets (ODTs) for pediatric and dysphagia patients, requiring high-purity API (>99%). This segment grew 25% in 2025.

Generic API production expansion: Chinese manufacturers (Shandong New Era, Chongqing Huapont) increased production capacity, reducing API prices by 10-15%.

Improved impurity profiling: New HPLC methods for trace impurity detection (limit 0.1%) meeting tightened EP/USP standards. Adoption grew 20% in 2025.

Policy driver – European Pharmacopoeia (EP) 11th edition (2025) : Updated bilastine monograph with stricter impurity limits, driving demand for high-purity API.

User case – Pediatric allergic rhinitis (EU) : A European pharmaceutical company launched bilastine orodispersible tablets (10mg) for children ≥6 years using high-purity API (>99%). Results: improved patient compliance (no water needed), successful regulatory approval (EMA), and 15% market share captured in first year.

Technical challenge – Bilastine solubility: Bilastine has pH-dependent solubility (low solubility at neutral pH). Solutions include:

Particle size reduction (micronization for tablets)

Amorphous solid dispersions (improved dissolution)

Cyclodextrin complexes (for oral solutions)

5. Competitive Landscape & Regional Dynamics

Company Headquarters Key Strength
Faes Farma Spain Originator; global leader
Menarini Group Italy European distribution
Bio-synth Switzerland High-purity API specialist
Lee Pharma India Asian generic API
METROCHEM API India Cost-competitive
Shandong New Era China Chinese domestic leader
Chongqing Huapont China API manufacturer
Regional dynamics:

Europe largest (45% market share), led by Spain (Faes Farma originator), Italy

Asia-Pacific fastest-growing (CAGR 9%), led by China (API manufacturing expansion), India

North America second (25%), with US generic market

Rest of World (10%), emerging

6. Segment Analysis by Purity and Application

Segment Characteristics 2024 Share CAGR (2026-2032)
By Purity
98%-99% Standard tablets ~40% 6.5%
Above 99% Premium, oral solutions ~60% 8%
By Application
Tablets Adult allergic rhinitis/urticaria ~80% 7%
Oral Solutions Pediatric, geriatric ~20% 8.5%
The high-purity (>99%) segment is fastest-growing (CAGR 8%). The oral solutions application leads growth (CAGR 8.5%).

7. Exclusive Industry Observation & Future Outlook

Why bilastine API demand is growing:

Factor Impact
Non-sedating profile Preferred over first-generation antihistamines
Once-daily dosing Improved patient compliance
Favorable safety profile No significant drug-drug interactions
Generic entry Lower cost, increased accessibility
Pediatric formulation expansion ODTs, oral solutions
API manufacturing process:

Step Process Quality Control
1 Chemical synthesis Intermediate purity
2 Purification (crystallization) Impurity removal
3 Drying & milling Particle size distribution
4 Final QC testing Purity, impurity profile, residual solvents
Impurity limits (EP/USP) :

Impurity Type Limit
Related substances (individual) ≤0.1%
Total impurities ≤0.5%
Residual solvents (Class 2) ≤300-3,000 ppm
Heavy metals ≤20 ppm
Global allergic rhinitis prevalence:

Region Prevalence Market Impact
Europe 20-30% High
North America 15-25% High
Asia-Pacific 10-20% Growing
Latin America 15-25% Moderate
Patent status:

Region Patent Expiry Generic Entry
Europe 2021-2022 2022-2023
US 2026-2027 Expected 2027-2028
Japan 2025-2026 2026-2027
Price trends:

Year API Price ($/kg) Trend
2020 600-700 Pre-generic
2024 450-500 Post-generic (Europe)
2027 (est) 300-400 US generic entry
Biosimilar/competitive landscape: Bilastine faces competition from established second-generation antihistamines (cetirizine, loratadine, fexofenadine) available as low-cost generics. Differentiation via safety profile (no QTc prolongation) and pediatric formulations.

By 2032, the bilastine API market is expected to exceed US$ 26.35 million at 7.3% CAGR.

Regional outlook:

Europe largest (45%), with originator presence

Asia-Pacific fastest-growing (CAGR 9%) — China API manufacturing

North America second (25%), with US generic market

Rest of World (10%), emerging

Key barriers:

Competition from established antihistamines (cetirizine, loratadine)

Food effect (reduced absorption with food)

Patent expiration (price erosion post-generic)

Pediatric data requirements (additional clinical trials)

API manufacturing complexity (multi-step synthesis)

Market nuance: The bilastine API market is growing steadily (7.3% CAGR) from a small base (32 metric tons, $16M in 2025). High-purity API (>99%) dominates (60% share) for oral solutions and premium tablets. Tablets (80% share) are largest application; oral solutions (20%) fastest-growing (8.5% CAGR). Europe leads (45%) with originator Faes Farma; Asia-Pacific fastest-growing (9% CAGR) with Chinese API manufacturing. Key trends: (1) orodispersible tablets, (2) high-purity API demand, (3) pediatric formulation expansion, (4) generic API production.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp